Market Newsdesk

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting drug-Fc conjugate (DFC), as well as the development of its novel DFCs from Cidara’s Cloudbreak^® platform, at the 2^nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.

“We are pleased to be presenting preclinical data demonstrating the potential of CD421, as well as on the utility and flexibility of our Cloudbreak DFC platform,” said Jeffrey Stein, Ph.D. president and chief executive officer of Cidara. “We believe CD421 combines the best attributes of small molecule and monoclonal antibody therapies and can serve as a potentially beneficial alternative treatment option for patients with cancer. We look forward to continuing to advance this candidate towards the clinic.”

Oral presentation details are as follows:

Title: Cidara Drug-Fc-Conjugates (DFCs): A new approach to treatment of cancer
Presenter: James Levin, Ph.D., Senior Director, Preclinical Development at Cidara Therapeutics
Session Date/Time: Thursday, June 22, 2023 at 9:30 a.m. ET
Session Location: Boston, MA

To view the full schedule, visit the Adenosine Pathway Targeted Cancer Immunotherapy Summit website here.

About Cloudbreak

^®

 DFCs

Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple targeted small molecule and peptide drugs to a human antibody fragment (Fc). These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system. In addition to multiple oncology programs, Cidara is advancing its antiviral DFC CD388 through Phase 1 and Phase 2a clinical trials in partnership with Janssen for the universal prevention and treatment of influenza.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including drug-Fc conjugates (DFCs) from its proprietary Cloudbreak^® platform targeting oncologic and viral diseases. In addition, Cidara recently received FDA approval for REZZAYO™ (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to whether the nonclincial data generated to date will be predictive of activity, safety or efficacy of CD421 or any CD73-targeted DFC in patients, and whether Cidara will be able to formulate a CD73-targeted DFC into a clinically acceptable form. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as delays in action by regulatory authorities due to limitations on inspections and other COVID-19-related effects, and impacts of the COVID-19 pandemic or other obstacles on the enrollment of patients or other aspects of rezafungin development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Investor Contact:

Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]

Media Contact:
Veronica Eames
LifeSci Communications
646-970-4682
[email protected]

RICHMOND, Va., June 20, 2023 (GLOBE NEWSWIRE) — Urban Grid, a Brookfield Renewable company and leading provider of clean energy, today named Randy Sawyer, formerly of EDP Renewables, as General Counsel. In addition, Jeff Hudson, former Director of Transmission Engineering for the firm, has been promoted to Vice President of Asset Management.

“I’ve spent nearly a decade supporting the hard work of decarbonizing the grid and my passion for it transcends the job,” said Sawyer. “Urban Grid is poised for extraordinary growth and the team is really building something new and that’s so exciting. To provide sound counsel and help guide the business through this phase and beyond is a huge and humbling opportunity.”

Sawyer began his career at the law firms of Holland & Knight and Latham & Watkins before joining EDP Renewables, where he spent 10 years, ultimately becoming Associate General Counsel, overseeing finance and tax equity transactions in addition to a broad swath of legal operations and streamlining processes in order to minimize project risk.

As Urban Grid’s first in-house counsel, Sawyer will develop an internal legal function that allows the team to remain nimble and innovative while navigating compliance and regulatory requirements. Further, he will help to establish processes and strategic relationships as the company forms new operating business units such as asset management under VP, Jeff Hudson. Jeff’s asset management experience at Duke Energy coupled with his leadership at Urban Grid make him a great fit to lead the rollout of this new department with the goal of safely operating our power plants, maintaining high reliability and incorporating an agrivoltaic land management program for world class operations.

“Our late-stage and in-construction projects are rapidly moving towards commercial operations and we’ll be ready to manage power generation by December,” said Peter Candelaria, Urban Grid CEO. “Under Jeff’s leadership, we’re building out operations to fully support our new solar facilities, off-take partners and–importantly–the local community for decades to come. I am honored to welcome Randy and Jeff to the expanding leadership team at Urban Grid.”

In January 2022, Brookfield Renewable U.S. acquired Urban Grid. The acquisition tripled Brookfield Renewable’s U.S. development to 31,000 megawatts of capacity and set Urban Grid on a course for growth. The acquisition has enabled Urban Grid to transition its development assets into operating facilities. Today, the platform spans the lifecycle of solar and energy storage development through project delivery, from site acquisition, community engagement, and development to engineering, construction, and commercialization. Urban Grid is actively preparing for the asset management process as projects enter construction.

Urban Grid

Urban Grid, a leading independent power producer, facilitates a rapid and sustainable energy transition by developing high-quality renewable energy projects, fostering community partnerships, and serving as a good land steward. Our company is positioned to own and operate its facilities while cultivating a land management system that benefits farmers, communities, and the natural world through agrivoltaics. Urban Grid maintains a delivery-focused approach with the goal of being a good neighbor, corporate citizen, and trusted energy solutions partner. Headquartered in Richmond, Virginia, with teams situated strategically throughout the United States, Urban Grid has a long history of contributing to the clean energy economy. In addition to 272.5 megawatts currently under construction, we are actively developing a growing portfolio of more than 15,000 megawatts of solar PV and 7,000 megawatts of co-located and stand-alone energy storage. For more, please visit www.urbangridsolar.com.

Urban Grid is a Brookfield Renewable company. Brookfield Renewable operates one of the world’s largest publicly traded, pure-play renewable power platforms.

Brookfield Renewable

Brookfield Renewable Brookfield Renewable operates one of the world’s largest publicly traded, pure-play renewable power platforms. Our portfolio consists of hydroelectric, wind, utility-scale solar and storage facilities in North America, South America, Europe and Asia, and totals approximately 31,600 megawatts of installed capacity and a development pipeline including approximately 131,900 megawatts of renewable power assets, 12 million metric tonnes per annum (“MMTPA”) of carbon capture and storage, 2 million tons of recycled material, 4 million metric million British thermal units of renewable natural gas pipeline, a solar manufacturing facility capable of producing 5,000 MW of panels annually and 1 MMTPA green ammonia facility powered entirely by renewable energy. Investors can access its portfolio either through Brookfield Renewable Partners L.P. (NYSE: BEP; TSX: BEP.UN), a Bermuda-based limited partnership, or Brookfield Renewable Corporation (NYSE, TSX: BEPC), a Canadian corporation. Brookfield Renewable is the flagship listed renewable power company of Brookfield Corporation, a leading global alternative asset manager with over $825 billion of assets under management.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c7093bb6-2fae-49cb-8e42-65de5a00bb3a

NEW BRAUNFELS, Texas, June 20, 2023 (GLOBE NEWSWIRE) — TaskUs, Inc. (Nasdaq: TASK), a leading provider of outsourced digital services and next-generation customer experience to the world’s most innovative companies, today announced recognition from workplace culture leader Comparably for its company leadership, inclusive values, and employee growth opportunities. Selected out of 70,000 companies across the U.S., TaskUs won across all four of this quarter’s categories including Best CEOs for Women, Best CEOs for Diversity, Best Leadership Team, and Best Career Growth.

This set of Comparably Awards is based on sentiment feedback provided by current employees who anonymously rated their employers on Comparably.com during a 12-month look-back period (May 15, 2022 through May 15, 2023). The final data set was compiled from over 20 million ratings across 70,000 companies.

“The Comparably recognition is incredibly meaningful to Us because it comes from the people who matter most – our nearly 48,000 employees,” said Bryce Maddock, Co-Founder and CEO of TaskUs. “Our people are at the heart of everything we do and ensuring a culture where everyone can thrive and be their best selves is what we’re all about. Serving our frontline employees enables Us to exceed client and customer expectations.”

“I was also particularly proud to see the Best Career Growth recognition,” continued Maddock. “Our leadership team is focused on giving our talented teammates growth opportunities so that they can build rewarding careers with TaskUs.”

The Comparably awards add to prestigious recognitions that TaskUs has received in 2023, including inclusion in the Gartner®, Market Guide for Customer Service and Support BPO Providers, March 2023 and being named a Leader and Star Performer in Everest Group’s Trust and Safety Services PEAK Matrix® Assessment 2023.

About Comparably

Comparably (now a ZoomInfo company) is a leading workplace culture and corporate brand reputation platform with over 20 million anonymous employee ratings on 70,000 companies. With the most comprehensive data on large and SMB organizations in nearly 20 different workplace categories – based on gender, ethnicity, age, experience, industry, location, education – it is one of the most used SaaS platforms for employer branding and a trusted third party site for workplace culture and compensation. For more information on Comparably and its annual Best Places to Work Awards, visit www.comparably.com.

About TaskUs
TaskUs is a leading provider of outsourced digital services and next-generation customer experience to the world’s most innovative companies, helping its clients represent, protect and grow their brands. Leveraging a cloud-based infrastructure, TaskUs serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ride-sharing, Technology, FinTech and HealthTech. As of March 31, 2023, TaskUs had a worldwide headcount of approximately 47,700 people across 27 locations in 13 countries, including the United States, the Philippines and India.

Investor Contact

Alan Katz
Investor Relations
[email protected] 

Media Contact

Lisa Wolford
Corporate communications
[email protected]

• Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin Pharmaceutical 
• Mr. Cooper is a former independent director of Sierra Oncology, acquired by GlaxoSmithKline for $1.9 billion in 2022 and Tobira Therapeutics, acquired by Allergan (now AbbVie) for $1.7 billion in 2016 

LOS ANGELES, June 20, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Jeffrey H. Cooper, former Chief Financial Officer of BioMarin Pharmaceutical Inc., has been appointed to the Company’s Board of Directors. Mr. Cooper brings significant leadership in finance, accounting, strategy, and mergers & acquisitions to Nexcella.

After joining BioMarin in 2003, Mr. Cooper held positions of increasing responsibility including Senior Vice President and Chief Financial Officer from 2007 until 2012. In addition to his experience at BioMarin, Mr. Cooper has served as an independent director of Sierra Oncology, acquired by GlaxoSmithKline for $1.9 billion in 2022; and Tobira Therapeutics, acquired by Allergan (now AbbVie) for $1.7 billion in 2016.

“We are thrilled to have Mr. Cooper join the Nexcella Board of Directors. He possesses a wealth of experience as the CFO of BioMarin and board member of other biotechnology firms which have been acquired,” said Ilya Rachman, MD, Ph.D., Chief Executive Officer of Immix Biopharma.  Gabriel Morris, Chief Financial Officer of Immix Biopharma, added: “Mr. Cooper’s 30 years of deep experience in finance and capital markets of pharmaceutical organizations will be an invaluable as we advance NXC-201 towards US clinical trials and global applications for regulatory approvals. We look forward to his contribution to our mission.”

“My decades of experience as a CFO and audit chair in the pharmaceutical industry are a natural fit for Nexcella to further enable bringing much needed cell therapies to patients,” said Mr. Cooper. “I look forward to working with the Nexcella team to advance its important technology to the next stage.”

During his career, Mr. Cooper served as Chief Financial Officer of KaloBios Pharmaceuticals, Inc.; Vice President of Finance at Matrix Pharmaceuticals; Corporate Controller at Foundation Health Systems; and Director of Business Analysis at Syntex Corporation. Mr. Cooper received a B.A. from the University of California, Los Angeles and an M.B.A. from Santa Clara University. He was a Certified Public Accountant (inactive status) in the state of California through 2021.

About Nexcella, Inc.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc (Nasdaq:IMMX), is a Los Angeles, CA based clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our lead candidate, next generation BCMA-targeted CAR-T NXC-201 for multiple myeloma and AL amyloidosis has produced 92% and 100% response rates in each indication, respectively, as of February 9, 2023 across 58 patients. We believe NXC-201 has potential to be the world’s first outpatient CAR-T. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at www.nexcella.com.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201 in multiple myeloma and AL Amyloidosis, which we believe could be the world’s first out-patient CAR-T. Our lead TSTx asset IMX-110, currently in Phase 1b/2a clinical trials as a monotherapy and IMMINENT-01 combination clinical trial with BeiGene’s anti-PD-1 antibody tislelizumab, holds Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the FDA. ImmixBio subsidiary Nexcella, Inc develops CAR-T NXC-201 for multiple myeloma and AL amyloidosis, with 92% and 100% response rates in each indication, respectively, as of February 9, 2023, currently being trialed in NEXICART-1. Learn more at www.immixbio.com.

Forward Looking Statements

This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Immix Biopharma, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements.

Contacts

Stern Investor Relations
Alex Lobo
Managing Director
[email protected]

Company Contact

[email protected]